Caxton Associates LLP Takes Position in Option Care Health, Inc. $OPCH

Key Points

• Caxton Associates LLP invested approximately $429,000 in Option Care Health by purchasing 12,268 shares during the 1st quarter, reflecting growing interest from institutional investors.
• Analysts have set a consensus rating of Moderate Buy for Option Care Health, with a target price of $35.75, supported by strong quarterly earnings that exceeded expectations.
• Insider activity shows significant purchasing, with directors acquiring over 23,000 shares in recent transactions, indicating confidence in the company's future performance.

Caxton Associates LLP purchased a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,268 shares of the company's stock, valued at approximately $429,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Compass Wealth Management LLC increased its holdings in Option Care Health by 8.9% in the 1st quarter. Compass Wealth Management LLC now owns 166,078 shares of the company's stock worth $5,804,000 after acquiring an additional 13,600 shares in the last quarter. Bessemer Group Inc. increased its holdings in Option Care Health by 62.3% in the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after acquiring an additional 599 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Option Care Health by 1.4% in the 1st quarter. Principal Financial Group Inc. now owns 485,871 shares of the company's stock worth $16,981,000 after acquiring an additional 6,616 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Option Care Health by 25.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 8,274 shares of the company's stock worth $289,000 after acquiring an additional 1,691 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Option Care Health by 307.1% in the 1st quarter. GAMMA Investing LLC now owns 3,192 shares of the company's stock worth $112,000 after acquiring an additional 2,408 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Option Care Health Trading Up 1.4%

OPCH traded up $0.38 during trading on Thursday, reaching $28.41. The company had a trading volume of 1,614,166 shares, compared to its average volume of 1,705,882. The stock has a market cap of $4.61 billion, a P/E ratio of 22.73, a PEG ratio of 1.71 and a beta of 0.82. The business has a 50 day simple moving average of $28.87 and a 200-day simple moving average of $31.29. Option Care Health, Inc. has a 52 week low of $21.39 and a 52 week high of $35.53. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The company had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.Option Care Health's revenue was up 15.4% on a year-over-year basis. During the same period last year, the company earned $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other Option Care Health news, Director Timothy P. Sullivan bought 20,000 shares of Option Care Health stock in a transaction on Thursday, August 21st. The shares were acquired at an average price of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the purchase, the director directly owned 49,229 shares in the company, valued at approximately $1,354,289.79. This trade represents a 68.43% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Harry M. Jansen Kraemer, Jr. bought 36,000 shares of Option Care Health stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $27.15 per share, for a total transaction of $977,400.00. Following the purchase, the director owned 375,390 shares of the company's stock, valued at approximately $10,191,838.50. This trade represents a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 59,411 shares of company stock worth $1,627,576 over the last quarter. Company insiders own 0.64% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on OPCH. Citigroup restated an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Barrington Research restated an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research note on Thursday, July 10th. Finally, JMP Securities increased their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.